1 Jin, Y. H. et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Mil Med Res 7, 4, doi:10.1186/s40779-020-0233-6 (2020).
2 Holshue, M. L. et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med 382, 929-936, doi:10.1056/NEJMoa2001191 (2020).
3 Yang, X. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med, doi:10.1016/S2213-2600(20)30079-5 (2020).
4 Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet 395, 497-506, doi:10.1016/s0140-6736(20)30183-5 (2020).
5 Chen, N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet 395, 507-513, doi:10.1016/s0140-6736(20)30211-7 (2020).
6 Wu, Z. & McGoogan, J. M. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA, doi:10.1001/jama.2020.2648 (2020).
7 Commission, G. O. o. N. H. a. H. Guideline of Diagnosis and Treatment of 2019 novel coronavirus pneumonia. (in Chinese) <http://www.gov.cn/zhengce/zhengceku/2020-03/04/content_5486705.htm> (2020).
8 Xiao, J. Z. et al. [Glucocorticoid-induced diabetes in severe acute respiratory syndrome: the impact of high dosage and duration of methylprednisolone therapy]. Zhonghua Nei Ke Za Zhi 43, 179-182 (2004).
9 Ni, Y. N., Chen, G., Sun, J., Liang, B. M. & Liang, Z. A. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Crit Care 23, 99, doi:10.1186/s13054-019-2395-8 (2019).
10 Li, Y. M. et al. [Factors of avascular necrosis of femoral head and osteoporosis in SARS patients' convalescence]. Zhonghua Yi Xue Za Zhi 84, 1348-1353 (2004).
11 Lee, N. et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol 31, 304-309, doi:10.1016/j.jcv.2004.07.006 (2004).
12 Lee, D. T. et al. Factors associated with psychosis among patients with severe acute respiratory syndrome: a case-control study. Clin Infect Dis 39, 1247-1249, doi:10.1086/424016 (2004).
13 Corneli, H. M. et al. A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis. N Engl J Med 357, 331-339, doi:10.1056/NEJMoa071255 (2007).
14 Arabi, Y. M. et al. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. Am J Respir Crit Care Med 197, 757-767, doi:10.1164/rccm.201706-1172OC (2018).
15 Zhou, W. et al. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal Transduct Target Ther 5, 18, doi:10.1038/s41392-020-0127-9 (2020).
16 WHO. Clinical management of severe acute respiratory infection (SARI) when COVID-19 is suspected, <https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected> (2020).
17 Russell, C. D., Millar, J. E. & Baillie, J. K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 395, 473-475, doi:10.1016/S0140-6736(20)30317-2 (2020).
18 Li, H. et al. Effect of low-to-moderate-dose corticosteroids on mortality of hospitalized adolescents and adults with influenza A(H1N1)pdm09 viral pneumonia. Influenza Other Respir Viruses 11, 345-354, doi:10.1111/irv.12456 (2017).
19 Chen, R. C. et al. Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience. Chest 129, 1441-1452, doi:10.1378/chest.129.6.1441 (2006).
20 Shang, L., Zhao, J., Hu, Y., Du, R. & Cao, B. On the use of corticosteroids for 2019-nCoV pneumonia. The Lancet 395, 683-684, doi:10.1016/s0140-6736(20)30361-5 (2020).
21 Tsang, O. T. et al. Coronavirus-positive nasopharyngeal aspirate as predictor for severe acute respiratory syndrome mortality. Emerg Infect Dis 9, 1381-1387, doi:10.3201/eid0911.030400 (2003).
22 Ho, J. C. et al. High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Am J Respir Crit Care Med 168, 1449-1456, doi:10.1164/rccm.200306-766OC (2003).
23 Meng, Q. H. et al. [Use of glucocorticoid in treatment of severe acute respiratory syndrome cases]. Zhonghua Yu Fang Yi Xue Za Zhi 37, 233-235 (2003).
24 Mehta, P. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet 395, 1033-1034, doi:10.1016/s0140-6736(20)30628-0 (2020).
25 Zha, L. et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust, doi:10.5694/mja2.50577 (2020).
26 Jones, B. M. et al. Prolonged disturbances of in vitro cytokine production in patients with severe acute respiratory syndrome (SARS) treated with ribavirin and steroids. Clin Exp Immunol 135, 467-473, doi:10.1111/j.1365-2249.2003.02391.x (2004).
27 Ruan, Q., Yang, K., Wang, W., Jiang, L. & Song, J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med, doi:10.1007/s00134-020-05991-x (2020).
28 Michot, J. M. et al. Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report. Ann Oncol, doi:10.1016/j.annonc.2020.03.300 (2020).
29 Luo, P. et al. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol, doi:10.1002/jmv.25801 (2020).
30 Cao, B. et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med, doi:10.1056/NEJMoa2001282 (2020).